Approximately 3 billion people, one half of the world’s population, live in at-risk regions for malaria infection leading to about 250 million malaria cases every year and nearly one million deaths. Once the malarial parasite Plasmodium vivax and Plasmodium falciparum enters the red blood cells its growth is inhibited by Proguanil, a prophylactic antimalarial drug which inhibits the enzyme, dihydrofolate reductase leading to the inhibition of the growth of malarial parasites. Considering the side effects of the antimalarial drugs, the present study was undertaken to substantiate the inhibition potential of mangrove-derived compounds against the receptor protein dihydrofolate reductase. Docking studies by using Argus lab software revealed that among nine mangrove-derived compounds five compounds namely stigmasterol, triterpenoid, tretinoin, pyrethrin and rubrolide-N showed good docking energy score of -14.2239, 12.4725, -11.689, -11.1828 and -10.884 Kcal/mol, respectively against dihydrofolate reductase.
Key words: Malaria, dihydrofolate reductase, mangrove-derived compounds, Pdb, Argus lab.
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0